mometasone-furoate and Eczema

Topics: Administration, Cutaneous; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Animals; Atrophy; Child; Child, Preschool; Clinical Trials as Topic; Controlled Clinical Trials as Topic; Cytokines; Dermatitis, Allergic Contact; Dermatitis, Atopic; Dermatitis, Irritant; Double-Blind Method; Drug Eruptions; Drug Evaluation, Preclinical; Eczema; Female; Guinea Pigs; Humans; Infant; Langerhans Cells; Male; Mice; Middle Aged; Mometasone Furoate; Multicenter Studies as Topic; Pituitary-Adrenal System; Pregnadienediols; Product Surveillance, Postmarketing; Randomized Controlled Trials as Topic; Rats; Skin

Atopic dermatitis (AD), chronic eczema, and pruritus hiemalis are a set of prevalent chronic xerotic skin disorders that share clinical features such as dryness, scales, and pruritus. A ceramide deficiency and defective epidermal functions are common in these diseases. This study was designed to assess the effect of ceramide-linoleic acid (LA-Cer)-containing moisturizer as an adjunctive therapy in the treatment of AD, chronic eczema, and pruritus hiemalis. In a 2-month study, patients with one of these three diseases were divided into two groups. The control group was treated with mometasone furoate (0.1%) cream (MF), whereas the treatment group received 0.1% MF in combination with an LA-Cer-containing moisturizer. Capacitance and transepidermal water loss were measured in normal and lesional skin, along with Eczema Assessment Severity Index and pruritus scores at Weeks 0, 2, 4, and 8. The results showed that tropical applications of an LA-Cer-containing moisturizer in combination with a topical glucocorticoid accelerated the reestablishment of epidermal permeability barrier and the amelioration of pruritus in patients with AD and pruritus hiemalis. However, it did not provide the same effect for chronic eczema. Thus, the efficacy of this combination therapy for this set of xerotic disorders requires further evaluation.

Topics: Administration, Cutaneous; Ceramides; Dermatitis, Atopic; Dermatologic Agents; Eczema; Electric Capacitance; Emollients; Glucocorticoids; Humans; Linoleic Acid; Mometasone Furoate; Pruritus; Severity of Illness Index; Treatment Outcome; Water Loss, Insensible

We have conducted an open label, non-comparative study in order to assess the efficacy and tolerability of Dexyane Med in combination with corticosteroids in patients with chronic hand eczema (CHE) and contact eczema (CE) in a real-life setting.. Twenty patients, 10 with CHE and 10 with CE, have been enrolled in the study. After the enrollment and the baseline evaluation, patients were treated with topical mometasone once daily and Dexyane Med once daily for one week, followed by Dexyane Med twice daily for three weeks. After the enrollment visit, patients were seen at the end of treatment, after four weeks. A telephone contact was foreseen at the second week. During the visits, mTLSS Score (CHE patients only), IGA Score and VAS for pruritus and pain were calculated. Patients' satisfaction was recorded during the phone contact after two weeks of treatment and at the final visit. Tolerability was evaluated at the end of the study.. All patients experienced a remarkable improvement in mTLSS Score, IGA Score (from a mean of 2.8 to 0.5) and VAS (from 4.5 to 0.6 for pruritus and from 2.9 to 0.3 for pain). The treatment was well tolerated and all patients were satisfied or very satisfied either at the second week or at the end of the study.. Our study has shown that the treatment of chronic hand eczema and contact eczema with a medical device administered twice a day for three weeks, following a one week treatment in combination with a topical corticosteroid, is effective in decreasing the burden of symptoms and well tolerated. To confirm our data, further controlled trials are warranted in order to explore the efficacy and tolerability of Dexyane Med in different types of eczema.

Topics: Adrenal Cortex Hormones; Adult; Chronic Disease; Dermatitis, Contact; Dermatologic Agents; Drug Therapy, Combination; Eczema; Equipment and Supplies; Female; Hand Dermatoses; Humans; Male; Mometasone Furoate; Pain; Pain Measurement; Patient Satisfaction; Pruritus; Treatment Outcome

Treatment with topical glucocorticoids in children with atopic eczema may be associated with systemic adverse effects, such as suppression of growth.. To asses if treatment with topical mometasone furoate 0.1% or topical tacrolimus 0.1% affects short-term growth in children with atopic eczema. Primary outcome measures were lower leg growth rates measured by knemometry.. Twenty 5- to 12-year-old prepubertal children with atopic eczema were included in a randomised, investigator-blind crossover study with five periods: two treatment periods, a run in, a wash out and a run out. All periods were of 2-week duration. The subjects applied mometasone furoate ointment 0.1% once daily during one treatment period and tacrolimus ointment 0.1% twice daily during the other treatment period.. As compared to run in mean lower leg growth rate during mometasone furoate and tacrolimus treatment was reduced by 0.09 and 0.06 mm/week, respectively, (F = 1.12, p = 0.35). Consistently, no statistically significant effects on urine levels of eosinophil protein X and crossed-linked N-telopeptides were detected.. Treatment with mometasone furoate or tacrolimus does not affect short-term growth in children with mild to moderate atopic eczema.

Topics: Administration, Topical; Anti-Allergic Agents; Bone Development; Child; Child, Preschool; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Eczema; Female; Growth Disorders; Humans; Immunosuppressive Agents; Leg; Male; Mometasone Furoate; Pregnadienediols; Severity of Illness Index; Tacrolimus; Time Factors; Treatment Outcome

Chronic hand eczema can be incapacitating, and there is little knowledge of the efficacy and safety of long-term treatment with topical corticosteroids. We compared the efficacy and safety of two different schedules for the treatment of chronic hand eczema with a potent topical corticosteroid, mometasone furoate. In a prospective, open, randomized trial, 120 patients with chronic hand eczema were treated daily with mometasone furoate fatty cream until the dermatitis cleared or for a maximum of 9 weeks. Those who cleared were randomized to treatment for up to 36 weeks with mometasone furoate on Sunday, Tuesday and Thursday (group A), mometasone furoate on Saturday and Sunday (group B) or no further corticosteroid treatment (group C). In the event of relapse, patients were permitted daily treatment with mometasone furoate for 3 weeks on two separate occasions. For 50 of 106 randomized patients, daily treatment for 3 weeks controlled their dermatitis; 29 needed 6 weeks and 27 needed 9 weeks of treatment. During the maintenance phase, 29 of 35 (83%) in group A, 25 of 37 (68%) in group B and nine of 34 (26%) in group C had no recurrences (P = 0.001, chi2-test). Side-effects were minimal. It is concluded that long-term, intermittent treatment of chronic hand eczema with mometasone furoate fatty cream is effective and safe.

Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Dermatitis, Allergic Contact; Dermatitis, Atopic; Dermatitis, Contact; Dermatitis, Irritant; Dermatitis, Occupational; Drug Administration Schedule; Eczema; Hand Dermatoses; Humans; Middle Aged; Mometasone Furoate; Pregnadienediols; Recurrence; Survival Analysis; Time Factors

Mometasone furoate [9a, 21-dichloro-llb, 17dihydroxy-16a-methyl-pregna-14-dione-3, 20-dione-17-(2furoate)] is a synthetic, 17-heterocyclic corticosteroid which has been shown to be highly effective as an anti-inflammatory agent which is approximately half as potent is suppressing hypothalamic-pituitary-adrenal (HPA) axis function as betamethasone valerate.. The present open, randomised, third party blinded, left-right sided study was designed to compare the therapeutic efficacy of mometasone furoate cream 0.1% with clobetasol propionate cream 0.05% applied twice daily in chronic eczema following a 3-week course of therapy.. Sixty consecutive patients with moderate to severe bilateral chronic eczema on the limbs were recruited into the study. The mean scores of various signs/symptoms including erythema, induration, crusting, scaling, excoriation and pruritus before and after 3 weeks treatment with mometasone furoate (MF) and clobetasol propionate (CP) cream, were compared. The baseline scores for MF and CP treated sites were almost identical. There was significant decrease in the mean scores of all signs/symptoms after 3 weeks treatment with MF and CP. There was also a significant difference in the mean scores between MF and CP treated sites after 3 weeks of treatment. The mean scores were significantly lower for CP treated sites than MF treated sites. More CP treated sites achieved "cleared" or "marked improvement" response than MF treated sites. There were more "excellent" or "good" grades on CP treated sites than MF treated sites at the end of 3 weeks of treatment. None of the patients showed any side-effects after 4 weeks of treatment.. Overall, 53% of patients considered the MF treated sites to be good or excellent vs 88% for CP treated sites.

Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Chronic Disease; Clobetasol; Drug Administration Schedule; Eczema; Female; Glucocorticoids; Humans; Male; Middle Aged; Mometasone Furoate; Pregnadienediols; Treatment Outcome

This retrospective study investigated the effectiveness of calamine lotion (CL) as an adjunctive therapy to mometasone furoate ointment (MFO) in the treatment of infant eczema (IE). This retrospective study analyzed the electronic medical records of 50 IE infants. They were allocated to a treatment group or a control group, with 25 subjects in each group. All infants in both groups received MFO. In addition, infants in the treatment group underwent CL. The outcomes were effectiveness based on the eczema area and severity index, lesion area, and pruritus severity. We analyzed the outcomes before and after treatment. The results of this study showed that infants in the treatment group had more effective in effectiveness based on eczema area and severity index (P < .01), lesion area (P < .01), and pruritus severity (P = .01) than those in the control group. However, no medical records reported any adverse events in either group. The results of this study showed that CL added to MFO was more effective than MFO alone in the treatment of infants with IE.

Topics: Dermatitis, Atopic; Eczema; Humans; Mometasone Furoate; Ointments; Pruritus; Retrospective Studies

Topics: Administration, Topical; Adrenal Cortex Hormones; Anti-Allergic Agents; Dermatitis, Atopic; Eczema; Humans; Mometasone Furoate

To explore the effects of Qingshi Cream, a compound traditional Chinese herbal medicine, on chronic dermatitis-eczema in mice induced by 2,4-dinitrochlorobenzene (DNCB).. Thirty BALB/C mice were randomly divided into vaseline group, 0.1% mometasone furoate cream group and Qingshi Cream group. Right ears of BALB/C mice were repeatedly challenged with 0.1% DNCB every three days for five times and previously sensitized with 7% DNCB to induce chronic dermatitis-eczema. Mice in different groups were applied Qingshi Cream, 0.1% mometasone furoate cream and vaseline respectively after each challenge. Weight difference of two ears, pathological change of right ear and dermal inflammatory cell number were used to assess the effects of the drugs.. After the 5th challenge, weight differences of two ears in the 0.1% mometasone furoate cream group and the Qingshi Cream group were significantly decreased as compared with that in the vaseline group. Changes such as ear swelling thickening and cellular infiltration in dermis were observed, and these features seemed to be more significant in the vaseline group as compared with the 0.1% mometasone furoate cream group and the Qingshi Cream group.. Qingshi Cream has an obvious effect in treatment of chronic dermatitis-eczema in mice.

Topics: Animals; Anti-Inflammatory Agents; Eczema; Medicine, Chinese Traditional; Mice; Mice, Inbred BALB C; Mometasone Furoate; Random Allocation

Atopic dermatitis (AD) is aggravated by mechanical irritation and bacterial colonization.. This study compared the efficacy of an antimicrobial silk fabric (DermaSilk) with that of a topical corticosteroid in the treatment of AD.. Fifteen children were enrolled and wore a dress, where the left side was made of DermaSilk and the right side was made of cotton. The right arm and leg were treated daily with the corticosteroid mometasone for 7 days. The treatment efficacy was measured with a modified EASI (Eczema Area and Severity Index) and with an assessment by the patients/parents and by a physician. All patients were evaluated at baseline, as well as 7 and 21 days after the initial examination.. All parameters showed that, irrespective of the treatment, there was a significant decrease of eczema after 7 days. No significant difference between DermaSilk-treated and corticosteroid-treated skin could be observed.. DermaSilk showed potential to become an effective treatment of AD.

Topics: Administration, Cutaneous; Anti-Allergic Agents; Anti-Bacterial Agents; Child; Child, Preschool; Clothing; Colony Count, Microbial; Dermatitis, Atopic; Eczema; Female; Humans; Infant; Male; Microbial Sensitivity Tests; Mometasone Furoate; Pregnadienediols; Silk; Staphylococcal Skin Infections; Staphylococcus aureus; Treatment Outcome